

# **2010 Symposium Presentations**

## **Session 1: Setting the Stage**

### **[Taking the NRC Vision Seriously](#)**

Martin Stephens (The Humane Society of the United States)

### **[The NRC Report: Its Vision and Strategy](#)**

Dan Krewski (University of Ottawa)

## **Session 2: Ongoing Initiatives Related to Implementing the NRC Vision: US Perspectives**

### **[The Tox21 Program](#)**

Raymond Tice (NIEHS)

### **[The ToxCast Program](#)**

Robert Kavlock (EPA)

## **Session 3: Ongoing Initiatives Related to 21st Century Toxicology: European and International Perspectives**

### **[Exploiting In Vitro Assay Technologies in the Development of Alternative Methods](#)**

Maurice Whelan (Joint Research Center)

### **[The EU AXLR8 Project](#)**

Horst Spielmann (Free University of Berlin)

### **[Trans-Atlantic Think-tank of Toxicology](#)**

Thomas Hartung (Johns Hopkins University)

## **Session 4: Ongoing Initiatives Related to Implementing the NRC Vision: Practical Applications**

### **[Unilever's Skin Sensitization Program](#)**

Cameron MacKay (Unilever)

### **[Risk21 Project](#)**

Tim Pastoor (Syngenta)

[\*A Pilot Project Approach to Implementing the Vision\*](#)

Melvin Andersen (Hamner Institute)

[\*A Systems Approach to Alternatives for Toxicity Testing\*](#)

George Daston (Procter & Gamble)

[\*How EPA is Incorporating 21st Century Toxicology into its Work\*](#)

Jack Fowle (US EPA)

**Session 5: The Big Picture**

[\*Lessons Learned from the Human Genome Project\*](#)

Christopher Austin (NIH)

[\*The Need for a Human Genome-type Project to Accelerate Implementation of the NRC Vision\*](#)

Andrew Rowan (HSUS)

**Session 7: Reports from Break-out Groups**

[\*B2: Are there ways to refine ongoing initiatives so that they make greater or faster contributions to implementing the NRC vision?\*](#)

[\*B4: Are current efforts sufficiently well-funded and coordinated internationally?\*](#)

**Session 8: Moving Forward**

**What are the overall recommendations that need to be put into action steps to accelerate implementation of the NRC vision?**

[\*A mechanistic re-definition of adverse effects –A key step in the toxicity testing paradigm shift\*](#)

Kim Boekelheide (Brown University)

[\*ACC Long-range Research Initiative \(LRI\)\*](#)

Tina Bahadori (American Chemistry Council)

[\*How to accelerate implementation? The view from a really big chemical company\*](#)

Ed Carney (Dow Chemical)

[\*Moving Forward\*](#)

